论文部分内容阅读
目的:探讨分析应用奥沙利铂联合氟脲嘧啶对胃癌患者进行辅助化疗的临床疗效。方法:选取2008年12月至2013年12月间我院收治的胃癌患者68例作为研究对象,将其随机分为对照组(34例)和观察组(34例),为对照组患者进行常规手术治疗,为观察组患者在进行手术治疗的基础上应用奥沙利铂和氟脲嘧啶对其进行辅助治疗,观察对比两组患者的临床疗效,并将对比的结果及两组患者的临床资料进行回顾性的分析。结果:经过8周的治疗,在34例对照组患者中,临床疗效判定等级为有效的患者有29例(占患者总数的85.3%),临床疗效判定等级为无效的患者有5例(占患者总数的14.7%)。在34例观察组患者中,临床疗效判定等级为有效的患者有32例(占患者总数的94.1%),临床疗效判定等级为无效的患者有2例(占患者总数的5.9%)。观察组患者的临床疗效明显优于对照组患者,差异显著(P<0.05),具有统计学意义。在34例观察组患者中,发生恶心呕吐的患者有1例,不良反应的发生率为2.9%。在34例对照组患者中,发生恶心呕吐的患者有2例(占患者总数的5.9%),发生血小板下降的患者有1例(占患者总数的2.9%),发生黏膜炎的患者有1例(占患者总数的2.9%),不良反应的发生率为11.8%。观察组患者的不良反应发生率明显低于对照组患者,差异显著(P<0.05),具有统计学意义。结论:应用奥沙利铂联合氟脲嘧啶对胃癌患者进行辅助化疗的临床疗效十分显著,值得在临床上推广应用。
Objective: To investigate the clinical efficacy of adjuvant chemotherapy with oxaliplatin plus fluorouracil in patients with gastric cancer. Methods: Sixty-eight patients with gastric cancer admitted to our hospital from December 2008 to December 2013 were randomly divided into control group (34 cases) and observation group (34 cases). Patients in control group were treated routinely Surgical treatment for the observation group patients in the surgical treatment based on the application of oxaliplatin and fluorouracil adjuvant treatment of the two groups were observed and compared the clinical efficacy and the results of the comparison and clinical data of two groups of patients Retrospective analysis. RESULTS: After 8 weeks of treatment, 29 of 34 patients (85.3% of patients) were rated as clinically effective and 34% of patients rated clinically effective as ineffective 14.7% of the total). Among the 34 patients in the observation group, 32 patients (94.1% of the total) had a clinically effective judgment grade, and 2 patients (5.9% of the total) had a clinically valid judgment grade of ineffectiveness. The clinical efficacy of the observation group was significantly better than that of the control group, the difference was significant (P <0.05), with statistical significance. In 34 patients in the observation group, nausea and vomiting occurred in 1 patient, the incidence of adverse reactions was 2.9%. Among the 34 control patients, 2 (5.9%) had nausea and vomiting, 1 had thrombocytopenia (2.9% of patients), 1 had mucositis (2.9% of the total number of patients), the incidence of adverse reactions was 11.8%. The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P <0.05), with statistical significance. Conclusion: The clinical effect of adjuvant chemotherapy with oxaliplatin and fluorouracil on gastric cancer patients is very significant, which is worth popularizing in clinic.